Steroid-free clinical remission was also higher in patients on vedolizumab at week 12, although rates of biochemical and fecal biomarker remission were comparable.
The number of therapies for moderate to severe UC has increased in recent years, but there are few data comparing different classes of compounds, said Gros. "There are currently no head-to-head randomized controlled trials for biologic drugs compared with small-molecule drugs inGros and her colleagues conducted a retrospective study of bio-naive patients with UC from the NHS Lothian region of Scotland who were given either tofacitinib or vedolizumab as their first advanced therapy.
Data on 158 patients were included, of whom 77 patients received tofacitinib and 81 patients received vedolizumab. Median follow-up for patients on vedolizumab was 3.1 years and 1.5 years for tofacitinib. Baseline characteristics were comparable, except for disease extent. "It's interesting that most patients on vedolizumab had extensive disease, while most patients on tofacitinib had left-side colitis or proctitis; this may have impacted the results," Gros said.The adjusted drug persistence at 12 months — the primary outcome — was 84% for the vedolizumab group vs 59.7% for the tofacitinib group was 23.4% for vedolizumab vs 13.0% for tofacinitib.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SFnewsnow - 🏆 237. / 63 Read more »
Source: NBCNewsHealth - 🏆 707. / 51 Read more »